A Study of Visilizumab in Subjects With Intravenous Steroid-Refractory Ulcerative Colitis

NCT00279422 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

TERMINATED

Status

127

Enrollment

INDUSTRY

Sponsor class

Stopped DMC recommendation, no efficacy

Conditions

Ulcerative Colitis

Interventions

DRUG: visilizumab
DRUG: visilizumab

Sponsor

Facet Biotech

Collaborators

[object Object]